SG10201912768YA - Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder - Google Patents
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorderInfo
- Publication number
- SG10201912768YA SG10201912768YA SG10201912768YA SG10201912768YA SG10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA
- Authority
- SG
- Singapore
- Prior art keywords
- prophylaxis
- treatment
- blood coagulation
- von willebrand
- willebrand factor
- Prior art date
Links
- 208000015294 blood coagulation disease Diseases 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
- 229960001134 von willebrand factor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198497 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912768YA true SG10201912768YA (en) | 2020-02-27 |
Family
ID=57389201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912768YA SG10201912768YA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| SG11201903954WA SG11201903954WA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903954WA SG11201903954WA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11890327B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3538134B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020504082A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190073576A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110381986B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017358865A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043397A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3538134T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2908008T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201912768YA (cg-RX-API-DMAC7.html) |
| TW (1) | TW201828974A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018087271A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CA3099049A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
| JP7780341B2 (ja) * | 2019-07-04 | 2025-12-04 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ） |
| JP7680442B2 (ja) | 2019-11-11 | 2025-05-20 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
| KR102647642B1 (ko) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | 혈액 응고 활성을 갖는 펩타이드와 이의 용도 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| ATE319817T1 (de) | 1996-04-24 | 2006-03-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| ES2233036T3 (es) | 1998-04-27 | 2005-06-01 | Opperbas Holding B.V. | Composicion farmaceutica que comprende factor viii y liposomas neutros. |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| CA2434097A1 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| ES2343681T3 (es) | 2002-04-29 | 2010-08-06 | Stichting Sanquin Bloedvoorziening | Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad. |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| DK1596887T3 (da) | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Faktor VIII-konjugat |
| AU2004239244C1 (en) | 2003-05-06 | 2015-04-23 | Bioverativ Therapeutics Inc. | Clotting factor-Fc chimeric proteins to treat hemophilia |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| NZ555032A (en) | 2004-11-12 | 2010-02-26 | Bayer Healthcare Llc | Site-directed modification of FVIII |
| DK1835938T3 (da) | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| WO2006108590A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| KR101641899B1 (ko) | 2006-06-14 | 2016-08-01 | 체에스엘 베링 게엠베하 | 혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질 |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| KR20100019999A (ko) | 2007-06-13 | 2010-02-19 | 체에스엘 베링 게엠베하 | 출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도 |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| KR101808751B1 (ko) | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| AU2012340501A1 (en) | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
| CN104411716B (zh) * | 2012-04-24 | 2018-09-07 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
| EP2841091A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| SG10201701037WA (en) | 2012-07-11 | 2017-03-30 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| DK2796145T3 (da) * | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| CN105452289A (zh) * | 2013-06-12 | 2016-03-30 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
| ES2895798T3 (es) | 2014-06-06 | 2022-02-22 | Octapharma Ag | Preparación que comprende péptidos del factor VIII y del factor Von Willebrand |
| JP6676551B2 (ja) | 2014-07-02 | 2020-04-08 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 改変フォンウィルブランド因子 |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
-
2017
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/da active
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en not_active Ceased
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/ko not_active Withdrawn
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/ja active Pending
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/zh active Active
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 TW TW106139051A patent/TW201828974A/zh unknown
- 2017-11-10 ES ES17801644T patent/ES2908008T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3538134A1 (en) | 2019-09-18 |
| ES2908008T3 (es) | 2022-04-27 |
| DK3538134T3 (da) | 2022-02-07 |
| WO2018087271A1 (en) | 2018-05-17 |
| US11890327B2 (en) | 2024-02-06 |
| TW201828974A (zh) | 2018-08-16 |
| SG11201903954WA (en) | 2019-05-30 |
| KR20190073576A (ko) | 2019-06-26 |
| US20210268071A1 (en) | 2021-09-02 |
| AU2017358865A1 (en) | 2019-05-09 |
| CA3043397A1 (en) | 2018-05-17 |
| JP2020504082A (ja) | 2020-02-06 |
| EP3538134B1 (en) | 2021-12-29 |
| CN110381986B (zh) | 2023-08-18 |
| CN110381986A (zh) | 2019-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201912768YA (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| PL3892631T3 (pl) | Białko fuzyjne do zastosowania w leczeniu choroby hvg | |
| IL258822A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| BR112017011722A2 (pt) | antagonistas de activina-actrii e usos para o tratamento de anemia | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| IL258259A (en) | Adjunctive therapy with 25-hydroxyvitamin d and articles therefor | |
| IL257751B (en) | Preparations to prevent the formation of blood clots and/or to treat thrombosis | |
| IL256077A (en) | Fragments of mutated ras protein | |
| SMT202300299T1 (it) | Nuovi polipeptidi e relativi usi medici | |
| IL257173A (en) | New insulin histories and their medical uses | |
| EP3362068C0 (en) | COMPOSITION OF A MIXTURE OF ANTIBACTERIAL AGENTS AND SHORT-TERM ANTIBACTERIAL TREATMENT REGIME INCLUDING LINEZOLIDE, BEDAQUILINE AND PRETOMANID | |
| IL255652A (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| EP3229859B8 (de) | Dialysemaschine zur überwachung zeitliche veränderungen des hämatokrits und/oder hämoglobinswertes. | |
| EP3684789A4 (en) | PROTEIN ENRICHED AND ZEINE DEPLETED | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| HUE059816T2 (hu) | Rekombináns hGH-t tartalmazó gyógyszerkészítmény gyermekkori növekedési hormon hiányának kezelésére | |
| LT3235503T (lt) | Kompozicija, turinti mišrų šilkmedžio uogų ir poria cocos žievės ekstraktą, skirta neurodegeneracinių sutrikimų prevencijai, pagerinimui arba gydymui | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| SG10201912360SA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| EP3525787A4 (en) | TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512 | |
| EP4046609C0 (en) | EXTENDED PHARMACOLOGICAL RELEASE OPHTHALMIC FORMULATION AND ITS USES | |
| SG11201703624PA (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers | |
| HK40013462A (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| EP3541208C0 (en) | NUTRITIONAL COMPOSITION FOR USE IN THERAPY OF CANCER PATIENTS | |
| PT3558381T (pt) | Composição líquida de fibrinogénio humano |